Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653136 | 0.92 | CA12 (0.45) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL13653133 | 0.91 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL13653146 | 0.89 | MAPT (0.52) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL13653109 | 0.87 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL13653140 | 0.85 | NPY1R (0.41) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL13653102 | 0.85 | MEN1 (0.42) | MEN1KMT2ARXFP1 | |
| SCHEMBL13653131 | 0.83 | TRPV1 (0.39) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL4184843 | 0.83 | MEN1 (0.40) | LMNAMEN1KMT2ANPY1RRXFP1 | |
| SCHEMBL13653130 | 0.83 | NAMPT (0.44) | NPY1RTRPV1 | |
| SCHEMBL4184838 | 0.82 | MTNR1A (0.41) | MEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | PDE4A 2342/4885PDE4B 2871/4885PDE4C 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.